MF59® -adjuvanted vaccines for seasonal and pandemic influenza prophylaxis

The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells

(2014) A. Seubert et al.   JOURNAL OF IMMUNOLOGY

Biology of Immune Responses to Vaccines in Elderly Persons

(2008) Birgit Weinberger et al.   CLINICAL INFECTIOUS DISEASES

Human infection with highly pathogenic H5N1 influenza virus

(2008) Andrea Gambotto et al.   LANCET

Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1

(2008) Iain Stephenson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular and cellular signatures of human vaccine adjuvants

(2008) F. Mosca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety of MF59™ adjuvant

(2008) Viola Schultze et al.   VACCINE

Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

(2008) Filippo Ansaldi et al.   VACCINE